Everything below concerns HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-22. Numbers and descriptions here follow the published literature rather than marketing material.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
Regulatory and pharmacopeial texts shape how HPLC testing is performed and documented. The International Council for Harmonisation provides validation guidance, while pharmacopeias publish general chromatography chapters and monographs for specific materials. Accreditation standards such as ISO/IEC 17025 address laboratory competence and traceability. Inspectors may review instrument qualification, analyst training, reference material control, and electronic records. Open questions include how best to validate methods for new complex products and how to handle automated data processing. Laboratories generally resolve these issues through risk assessment, method lifecycle management, and documented scientific justification.
In quality control laboratories, HPLC testing supports batch release, raw material checks, stability studies, and impurity profiling. A validated method defines sample preparation, instrument settings, calibration, and acceptance criteria. Analysts compare results with specifications and investigate out-of-specification outcomes before a batch is approved. Documentation includes chromatograms, integration records, audit trails, and reagent details. Because results influence product decisions, laboratories follow formal quality systems and data integrity rules. The exact tests and limits depend on the material, its intended use, and the applicable regulatory framework.
Detection in HPLC testing commonly relies on ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. UV detection is widely used because many organic compounds absorb light, but it requires a chromophore. Mass spectrometry provides mass-based identification and high sensitivity for trace analytes. Each detector has trade-offs in selectivity, cost, and compatibility with mobile phases. Quantification typically uses calibration curves prepared from reference standards. Results are reported as concentration, purity, or presence above a limit.
HPLC testing separates dissolved compounds by passing a liquid sample through a column packed with stationary phase. A pump delivers mobile phase at controlled flow, and the sample components interact differently with stationary and mobile phases. Compounds that spend more time in mobile phase elute earlier; those retained by stationary phase elute later. Detectors record elution as peaks, and peak area or height relates to amount. This mechanism underpins quantitative analysis of mixtures.
Most routine HPLC testing uses reversed-phase columns, where the stationary phase is nonpolar and the mobile phase is a polar mixture such as water with an organic solvent. Analytes partition between the two phases according to polarity, size, and charge. Gradients that change solvent composition over time can separate compounds with broad retention ranges. Isocratic conditions keep solvent composition constant and suit simpler mixtures. The choice of column chemistry, pH, and temperature affects selectivity and peak shape.
| Property | Value | Notes |
|---|---|---|
| Primary guidance | ICH Q2(R2) | Analytical procedure validation |
| Compendial chapter | USP <621> | Chromatography general chapter |
| Validation parameter | Accuracy | Closeness to accepted true value |
| System suitability check | Peak resolution | Ensures separation between adjacent peaks |
| Data record | Audit trail | Supports data integrity and traceability |
Validation demonstrates that a method is suitable for its intended use. Typical performance characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulators and standards organizations provide frameworks, but specific requirements depend on the application and jurisdiction. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, retention time repeatability, and sensitivity. A validated method is not permanently fixed; changes may require partial or full revalidation.
Routine HPLC testing depends on controlled reagents, calibrated instruments, and documented procedures. Columns degrade over time, so retention times and peak shapes are monitored for drift. Mobile phases are filtered and degassed to prevent pump damage and detector noise. Reference standards must be traceable and stored under suitable conditions. Data handling systems record injections, calculations, and audit trails. Quality control samples interspersed with unknowns help detect errors during a run.
HPLC testing is an analytical technique used to separate, identify, and quantify components in a liquid sample. It relies on a pressurized mobile phase that carries the sample through a column packed with stationary phase. Different compounds travel at different rates because of interactions with the stationary and mobile phases. The resulting signal versus time is a chromatogram. Peak position indicates identity under specified conditions, while peak area or height relates to amount.
Laboratories apply HPLC testing across pharmaceutical, food, environmental, and industrial chemistry. The method can measure active ingredients, impurities, additives, preservatives, and degradation products. Sample preparation often includes dilution, filtration, and sometimes extraction or derivatization. The choice of column, mobile phase, pH, temperature, and detector depends on the analytes and matrix. Results are compared with reference standards to assign identity and concentration. Method suitability is judged by resolution, precision, and accuracy.
Developing an HPLC test begins with defining the analytes, matrix, and required reporting limits. Chemists select a separation mode, column chemistry, mobile phase composition, flow rate, and detection wavelength or mass transition. Experiments then adjust these variables to achieve adequate retention, resolution, and peak shape. System suitability tests confirm that the instrument and method perform consistently before sample analysis. Without suitable resolution, quantitative results may be unreliable. Preliminary runs often use scouting gradients to locate retention windows.
Validation establishes that a method is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, robustness, and stability of standards and samples. Acceptance criteria are defined in advance, and results are documented in a validation report. Regulatory guidance for pharmaceuticals, foods, and environmental testing differs, so the applicable framework must be identified. Ongoing verification uses control samples and trend charts after validation. Method transfer to another laboratory may require partial revalidation.
Routine quality control includes blanks, duplicates, spiked samples, and certified reference materials. Calibration curves are prepared with standards at several concentrations, and the detector response is checked for linearity. Carryover, column aging, mobile phase evaporation, and temperature drift can shift retention times or peak areas. Maintenance such as replacing seals, filters, and columns helps prevent failures. Records of injections, integration, and deviations support traceability. Audits may request raw data and instrument logs for each batch.
Insulin may not be necessary and it may be possible to switch a person from insulin injections to oral agents without loss of glycemic control. It may prompt screening of relatives and so help identify other cases in family members. As it occurs infrequently, many cases of MODY are initially assumed to be more common forms of diabetes: type 1 if the patient is young and not overweight, type 2 if the patient is overweight, or gestational diabetes if the patient is pregnant. Standard diabetes treatments (insulin for type 1 and gestational diabetes, and oral hypoglycemic agents for type 2) are often initiated before the doctor suspects a more unusual form of diabetes.
== Education == Burnham earned her Ph.D. in medical sciences at the University of Alberta in 2007. Later, she pursued fellowship training in clinical microbiology at Washington University in St. Louis, which she completed in 2009.
As of 2016, there were more than 430 Hooters locations and franchises around the world, and Hooters of America LLC owns 160 units. In 2012, there were Hooters locations in 44 US states, the United States Virgin Islands, Guam, and 28 other countries. Hooters also had an airline, Hooters Air, with a normal flight crew and flight attendants and scantily clad "Hooters Girls" on every flight. On March 31, 2025, Hooters of America, Inc. announced that it had filed for Chapter 11 bankruptcy protection.
=== Vasodilation === Substance P is a potent vasodilator. Substance P–induced vasodilation is dependent on nitric oxide release. Substance P is involved in the axon reflex-mediated vasodilation to local heating and wheal and flare reaction. It has been shown that vasodilation to Substance P is dependent on the NK1 receptor located on the endothelium. In contrast to other neuropeptides studied in human skin, Substance P–induced vasodilation has been found to decline during continuous infusion. This possibly suggests an internalization of neurokinin-1 (NK1). As is typical with many vasodilators, it also has bronchoconstrictive properties, administered through the non-adrenergic, non-cholinergic nervous system (branch of the vagal system).
Glucagon/gastric inhibitory polypeptide/secretin/vasoactive intestinal peptide hormones are a family of evolutionarily related peptide hormones that regulate activity of G-protein-coupled receptors from the secretin receptor family. A number of polypeptidic hormones, mainly expressed in the intestine or the pancreas, belong to a group of these structurally related peptides. This family of hormones are produced from (preproglucagon), which is cleaved to produce glucagon, glucagon-like protein I, glucagon-like protein II, and glicentin. Other members of the structurally similar group include secretin, gastric inhibitory peptide, vasoactive intestinal peptide, prealbumin, peptide HI-27, and growth hormone releasing factor. One hormone, glucagon, is fully conserved in all mammalian species in which it has been studied.
Sources: en.wikipedia.org
The Industrial Revolution in Japan occurred during the Meiji era. The industrial revolution began around 1870 as Meiji era leaders decided to catch up with the West. The government built its first railroads, improved roads, and inaugurated a land reform program to prepare the country for further development. It inaugurated a new Western-based education system for all young people, sent thousands of students to the United States and Europe, and hired more than 3,000 Westerners to teach modern science, mathematics, technology, and foreign languages in Japan (O-yatoi gaikokujin). In 1871, a group of Japanese politicians known as the Iwakura Mission toured Europe and the US to learn western ways. The result was a deliberate state-led industrialization policy to enable Japan to quickly catch up. Japan developed modern industry through direct state intervention. Government-owned enterprises were important to the development of key economic sectors like railways. Through government connections, major private enterprises received various forms of financial support from the state. Modern industry first appeared in textiles, including cotton and especially silk, which was based in home workshops in rural areas. Due to the importing of new textile manufacturing technology from Europe, between 1886 and 1897, Japan's total value of yarn output rose from 12 million to 176 million yen. In 1886, 62% of yarn in Japan was imported; by 1902, most yarn was produced locally.
Xerophthalmia, caused by a severe vitamin A deficiency, is described by pathologic dryness of the conjunctival epithelium and cornea. The conjunctiva becomes dry, thick, and wrinkled. Indicative is the appearance of Bitot's spots, which are clumps of keratin debris that build up inside the conjunctiva. If untreated, xerophthalmia can lead to dry eye syndrome, corneal ulceration and ultimately to blindness as a result of cornea and retina damage. Although xerophthalmia is an eye-related issue, prevention (and reversal) are functions of retinoic acid having been synthesized from retinal rather than the 11-cis-retinal to rhodopsin cycle. Throughout southeast Asia, estimates are that more than half of children under the age of six years have subclinical vitamin A deficiency and night blindness, with progression to xerophthalmia being the leading cause of preventable childhood blindness. Estimates are that each year there are 350,000 cases of childhood blindness due to vitamin A deficiency. The causes are vitamin A deficiency during pregnancy, followed by low transfer of vitamin A during lactation and infant/child diets low in vitamin A or β-carotene. The prevalence of pre-school age children who are blind due to vitamin A deficiency is lower than expected from incidence of new cases only because childhood vitamin A deficiency significantly increases all-cause mortality.
The outbreak of the French Revolution had been received with great alarm by the rulers of Europe's continental powers, further exacerbated by the execution of Louis XVI, and the overthrow of the French monarchy. In 1793, Austria, the Kingdom of Sardinia, the Kingdom of Naples, Prussia, the Kingdom of Spain, and the Kingdom of Great Britain formed the First Coalition to curtail the growing power of revolutionary France. Measures such as mass conscription, military reforms, and total war allowed France to defeat the coalition, despite the concurrent civil war in France. Napoleon, then a general of the French Revolutionary Army, forced the Austrians to sign the Treaty of Campo Formio, leaving only Great Britain opposed to the fledgling French Republic. A Second Coalition was formed in 1798 by Great Britain, Austria, Naples, the Ottoman Empire, the Papal States, Portugal, Russia, and Sweden. The French Republic, under the Directory, suffered from heavy levels of corruption and internal strife. The new republic also lacked funds, no longer enjoying the services of Lazare Carnot, the minister of war who had guided France to its victories during the early stages of the Revolution. Napoleon Bonaparte, commander of the Armée d'Italie in the latter stages of the First Coalition, had launched a campaign in Egypt, intending to disrupt the British control of India. Pressed from all sides, the Republic suffered a string of successive defeats against revitalised enemies, who were supported by Britain's financial help.
== M == MACF1 MacMARKS Mena Myopodin MAP1A Merlin (related to the ERM proteins) Myosins MAP-1C Metavinculin Moesin (the M of ERM proteins) Myosin light chain kinase MAL Mip-90 Myosin Light Chain A1 MARKS MIM MAYP Mycalolide (a macroglide drug) Mayven Myelin basic protein
Sources: en.wikipedia.org
== Further reading == Zachara, Natasha; Akimoto, Yoshihiro; Hart, Gerald W. (2015), Varki, Ajit; Cummings, Richard D.; Esko, Jeffrey D.; Stanley, Pamela (eds.), "The O-GlcNAc Modification", Essentials of Glycobiology (3rd ed.), Cold Spring Harbor Laboratory Press, PMID 28876858.
In 1952, iproniazid, an antimycobacterial agent, was discovered to have psychoactive properties while researched as a possible treatment for tuberculosis. Researchers noted that patients given iproniazid became cheerful, more optimistic, and more physically active. Soon after its development, iproniazid and related substances were shown to slow enzymatic breakdown of serotonin, dopamine, and norepinephrine via inhibition of the enzyme monoamine oxidase. For this reason, this class of drugs became known as monoamine oxidase inhibitors, or MAOIs. During this time development of distinctively different antidepressant agents was also researched. Imipramine became the first clinically useful tricyclic antidepressant (TCA). Imipramine was found to affect numerous neurotransmitter systems and to block the reuptake of norepinephrine and serotonin from the synapse, therefore increasing the levels of these neurotransmitters. Use of MAOIs and TCAs gave major advances in treatment of depression but their use was limited by unpleasant side effects and significant safety and toxicity issues. Throughout the 1960s and 1970s, the catecholamine hypothesis of emotion and its relation to depression was of wide interest and that the decreased levels of certain neurotransmitters, such as norepinephrine, serotonin, and dopamine might play a role in the pathogenesis of depression. This led to the development of fluoxetine, the first SSRI.
=== Legal status === Paclitaxel was approved for medical use in the European Union in 2008. In November 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Naveruclif, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer. The applicant for this medicinal product is Accord Healthcare S.L.U. Naveruclif was approved for medical use in the European Union in January 2024. In May 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Apexelsin, intended for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and non-small cell lung cancer. The applicant for this medicinal product is WhiteOak Pharmaceutical B.V. Apexelsin was approved for medical use in the European Union in July 2024.
Sources: en.wikipedia.org
System suitability is a set of checks performed before and during an HPLC run to confirm that the instrument and method are working as expected. It may include retention time repeatability, resolution between peaks, peak symmetry, and signal intensity. Failing suitability criteria usually invalidates the run.
An HPLC method is typically validated before its routine use and revalidated in part when significant changes affect the method. Regulators do not set a universal calendar interval. The need for revalidation depends on the change, its risk, and the applicable guidance.
Validation establishes that a method is suitable for its intended purpose, often through a planned study. Verification confirms that a laboratory can reproduce a previously validated or compendial method under its own conditions. Verification is usually narrower than full validation.
It separates components in a liquid sample and measures their amounts using a detector. Results can indicate concentration, purity, or identity based on retention time and detector response. The technique works for mixtures that can be dissolved and filtered.